Cargando…
Clinical trial update: International Breast Cancer Study Group
The International Breast Cancer Study Group (IBCSG) has been conducting large, phase III clinical trials since 1978. Prior to 1986, these activities were carried out under the name of Ludwig Breast Cancer Study Group. Seven trials of adjuvant therapies are currently open for patient accrual, five of...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2005
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1410774/ https://www.ncbi.nlm.nih.gov/pubmed/16280051 http://dx.doi.org/10.1186/bcr1334 |
| _version_ | 1782127071469764608 |
|---|---|
| author | Price, Karen N Goldhirsch, Aron |
| author_facet | Price, Karen N Goldhirsch, Aron |
| author_sort | Price, Karen N |
| collection | PubMed |
| description | The International Breast Cancer Study Group (IBCSG) has been conducting large, phase III clinical trials since 1978. Prior to 1986, these activities were carried out under the name of Ludwig Breast Cancer Study Group. Seven trials of adjuvant therapies are currently open for patient accrual, five of which are described in this report. The IBCSG has been a leader in the field of tailored treatment approaches for specific subpopulations of patients with breast cancer, believing that what is best for the majority may not be best for a defined minority. |
| format | Text |
| id | pubmed-1410774 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2005 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-14107742006-03-24 Clinical trial update: International Breast Cancer Study Group Price, Karen N Goldhirsch, Aron Breast Cancer Res Commentary The International Breast Cancer Study Group (IBCSG) has been conducting large, phase III clinical trials since 1978. Prior to 1986, these activities were carried out under the name of Ludwig Breast Cancer Study Group. Seven trials of adjuvant therapies are currently open for patient accrual, five of which are described in this report. The IBCSG has been a leader in the field of tailored treatment approaches for specific subpopulations of patients with breast cancer, believing that what is best for the majority may not be best for a defined minority. BioMed Central 2005 2005-10-04 /pmc/articles/PMC1410774/ /pubmed/16280051 http://dx.doi.org/10.1186/bcr1334 Text en Copyright © 2005 BioMed Central Ltd |
| spellingShingle | Commentary Price, Karen N Goldhirsch, Aron Clinical trial update: International Breast Cancer Study Group |
| title | Clinical trial update: International Breast Cancer Study Group |
| title_full | Clinical trial update: International Breast Cancer Study Group |
| title_fullStr | Clinical trial update: International Breast Cancer Study Group |
| title_full_unstemmed | Clinical trial update: International Breast Cancer Study Group |
| title_short | Clinical trial update: International Breast Cancer Study Group |
| title_sort | clinical trial update: international breast cancer study group |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1410774/ https://www.ncbi.nlm.nih.gov/pubmed/16280051 http://dx.doi.org/10.1186/bcr1334 |
| work_keys_str_mv | AT pricekarenn clinicaltrialupdateinternationalbreastcancerstudygroup AT goldhirscharon clinicaltrialupdateinternationalbreastcancerstudygroup AT clinicaltrialupdateinternationalbreastcancerstudygroup |